PlasmonicTron Co. Ltd.
Update：2026/11/10
Industries
Main Industry
Biotechnology
Main Product/Service
Currently focused on retinal organoid development, providing:
Retinal organoid samples suitable for bulk production
Quality validation reports including structural metrics
Retinal organoid samples suitable for bulk production
Quality validation reports including structural metrics
The content above was translated by Ai
Founded Year
2020
Unified Business No.
83464716
Status
Active
Number of Employees
0
Total Paid-in
Capital
63,210,000 (NT$)
Location of Company
Taiwan
, Taipei City
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
PlasmonicTron provides the critical biological infrastructure—industrial-scale Organoids—to power the next decade of biotech innovation and Regenerative Medicine. We solve the industry's primary bottleneck: achieving high-consistency and reliability in organoid bioprocessing. By integrating ML-driven process control and automated cultivation, we transform manual workflows into standardized, regulatory-grade manufacturing. From NAMs-aligned drug screening to advanced scaffolds for regenerative therapies, PlasmonicTron is the industrialized total solution for biopharma and clinical partners seeking to scale biological models and accelerate the future of precision medicine.
The content above was translated by Ai
